Stephen MacMillan - Boston Scientific Independent Director
| BSX Stock | USD 103.04 0.33 0.32% |
Director
Mr. Stephen P. MacMillan is Independent Director of the Company. Mr. MacMillan is currently the Chairman, President and Chief Executive Officer of Hologic, Inc., a position he has held since June 2015, and he served as President and Chief Executive Officer of Hologic, Inc., since December 2013. Prior to assuming his role with Hologic, Mr. MacMillan was the Chief Executive Officer of sBioMed, LLC, a medical research company, from October 2012 to December 2013. From 2003 to 2012, Mr. MacMillan served in various roles at Stryker Corporationrationration, including Chief Operating Officer from June 2003 to January 2005, President from June 2003 to February 2012, Chief Executive Officer from January 2005 to February 2012 and Chairman from January 2010 to February 2012. Prior to 2003, Mr. MacMillan was a senior executive with Pharmacia Corporationrationration, where he oversaw five global businesses. Prior to joining Pharmacia, Mr. MacMillan spent 11 years with Johnson Johnson in a variety of senior roles both in the U.S. and Europe, including President of the joint venture between Johnson Johnson and Merck. Mr. MacMillan began his career with Procter Gamble in 1985. Mr. MacMillan formerly served as a director of Texas Instruments Inc. and Alere Inc. Mr. MacMillan also serves on the Board of Directors of Advamed, a medical device trade association. since 2015.
| Age | 56 |
| Tenure | 10 years |
| Address | 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234 |
| Phone | 508 683 4000 |
| Web | https://www.bostonscientific.com |
Stephen MacMillan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Stephen MacMillan against Boston Scientific stock is an integral part of due diligence when investing in Boston Scientific. Stephen MacMillan insider activity provides valuable insight into whether Boston Scientific is net buyers or sellers over its current business cycle. Note, Boston Scientific insiders must abide by specific rules, including filing SEC forms every time they buy or sell Boston Scientific'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Stephen MacMillan over six months ago Disposition of 12000 shares by Stephen MacMillan of Hologic subject to Rule 16b-3 |
Boston Scientific Management Efficiency
The company has Return on Asset of 0.049 % which means that on every $100 spent on assets, it made $0.049 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0892 %, implying that it generated $0.0892 on every 100 dollars invested. Boston Scientific's management efficiency ratios could be used to measure how well Boston Scientific manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Boston Scientific's Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.14 in 2025, whereas Return On Assets are likely to drop 0.05 in 2025. At this time, Boston Scientific's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 34.6 B in 2025, whereas Other Current Assets are likely to drop slightly above 544.2 M in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jacqueline Kosecoff | STERIS plc | 71 | |
| Roch Doliveux | Stryker | 64 | |
| Gail Boudreaux | Zimmer Biomet Holdings | 59 | |
| Roxanne Austin | Abbott Laboratories | 60 | |
| Angela Fuente | Edwards Lifesciences Corp | N/A | |
| Kendall Powell | Medtronic PLC | 66 | |
| Nirav Shah | STERIS plc | 47 | |
| Betsy Bernard | Zimmer Biomet Holdings | 65 | |
| Katarzyna MazurHofsaess | Smith Nephew SNATS | 57 | |
| John Rogers | Smith Nephew SNATS | 56 | |
| Sally Blount | Abbott Laboratories | 59 | |
| Marc Owen | Smith Nephew SNATS | 61 | |
| Loyal Wilson | STERIS plc | 70 | |
| Nancy McKinstry | Abbott Laboratories | 62 | |
| Robert Alpern | Abbott Laboratories | 70 | |
| Martha Marsh | Edwards Lifesciences Corp | 72 | |
| Andrew Silvernail | Stryker | 50 | |
| Rajeev Suri | Stryker | 53 | |
| Robin Freestone | Smith Nephew SNATS | 61 | |
| Steven Loranger | Edwards Lifesciences Corp | 69 | |
| Patricia Gonzalez | Abbott Laboratories | 49 | |
Management Performance
| Return On Equity | 0.0892 | ||||
| Return On Asset | 0.049 |
Boston Scientific Corp Leadership Team
Elected by the shareholders, the Boston Scientific's board of directors comprises two types of representatives: Boston Scientific inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Boston. The board's role is to monitor Boston Scientific's management team and ensure that shareholders' interests are well served. Boston Scientific's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Boston Scientific's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Ludwig, Lead Independent Director | ||
| Donna James, Independent Director | ||
| Stephen MacMillan, Independent Director | ||
| Michael Mahoney, Chairman of the Board, President, Chief Executive Officer | ||
| Emily Woodworth, Global VP | ||
| Kevin Ballinger, Executive Vice President and Global President - Interventional Cardiology | ||
| Desiree RallsMorrison, Senior Vice President General Counsel, Corporate Secretary | ||
| Maulik Nanavaty, Senior Vice President and President - Neuromodulation | ||
| Ian Meredith, Executive Vice President Global Chief Medical Officer | ||
| David Pierce, Executive Vice President and President, MedSurg and President - Endoscopy | ||
| Ellen Zane, Independent Director | ||
| Joseph Fitzgerald, Executive Vice President, President, Interventional Cardiology | ||
| Eric Thepaut, Executive Vice President and President - Europe, Middle East and Africa | ||
| Daniel Brennan, CFO, Principal Accounting Officer and Executive VP | ||
| Nelda Connors, Independent Director | ||
| Wendy Carruthers, Executive Vice President - Human Resources | ||
| Jodi Eddy, Senior Vice President and Chief Information and Digital Officer | ||
| Catherine Jennings, VP Interventions | ||
| John Sorenson, Senior Vice President - Manufacturing and Supply Chain | ||
| Arthur Butcher, Executive Vice President and President, Asia Pacific | ||
| Daniel CPA, Executive CFO | ||
| Edward Mackey, Executive Vice President - Global Operations | ||
| Scott Olson, Senior Vice President, President - Cardiac Rhythm Management and Diagnostics | ||
| Vance Brown, Senior Vice President General Counsel, Corporate Secretary | ||
| Charles Dockendorff, Independent Director | ||
| Mary Moynihan, Senior Officer | ||
| John Sununu, Independent Director | ||
| Jeffrey Mirviss, Executive Vice President and President - Peripheral Interventions | ||
| Yoshiaki Fujimori, Independent Director | ||
| David Wichmann, Independent Director | ||
| David Roux, Independent Director | ||
| Susan Lisa, VP, Investor Relations | ||
| Jonathan Monson, Chief Accounting Officer, Vice President Global Controller | ||
| Jeffrey MBA, Executive Interventions | ||
| Meghan Scanlon, Senior Vice President and President - Urology and Pelvic Health |
Boston Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Boston Scientific a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0892 | ||||
| Return On Asset | 0.049 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 160.13 B | ||||
| Shares Outstanding | 1.47 B | ||||
| Shares Owned By Insiders | 0.17 % | ||||
| Shares Owned By Institutions | 92.28 % | ||||
| Number Of Shares Shorted | 14.4 M | ||||
| Price To Earning | 107.05 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Boston Stock Analysis
When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.